Literature DB >> 30927136

Erenumab: from scientific evidence to clinical practice-the first Italian real-life data.

Piero Barbanti1,2, Cinzia Aurilia3, Gabriella Egeo3, Luisa Fofi3.   

Abstract

Year:  2019        PMID： 30927136     DOI： 10.1007/s10072-019-03839-x

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  15 in total

Review 1.  Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review.

Authors:  Ann M Murray; Jennifer I Stern; Carrie E Robertson; Chia-Chun Chiang
Journal:  Curr Pain Headache Rep       Date:  2022-09-05

2.  Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region.

Authors:  Raffaele Ornello; Alfonsina Casalena; Ilaria Frattale; Valeria Caponnetto; Amleto Gabriele; Giannapia Affaitati; Maria Adele Giamberardino; Maurizio Assetta; Maurizio Maddestra; Fabio Marzoli; Stefano Viola; Davide Cerone; Carmine Marini; Francesca Pistoia; Simona Sacco
Journal:  J Headache Pain       Date:  2020-08-15       Impact factor: 7.277

3.  Assessment of the Effect of Erenumab on Efficacy and Quality-of-Life Parameters in a Cohort of Migraine Patients With Treatment Failure in Cyprus.

Authors:  Andria Tziakouri; Haritini Tsangari; Costas Michaelides
Journal:  Front Neurol       Date:  2021-07-29       Impact factor: 4.003

4.  Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.

Authors:  Armin Scheffler; Olga Messel; Sebastian Wurthmann; Michael Nsaka; Christoph Kleinschnitz; Martin Glas; Steffen Naegel; Dagny Holle
Journal:  J Headache Pain       Date:  2020-07-03       Impact factor: 7.277

5.  Association between response to triptans and response to erenumab: real-life data.

Authors:  Ilaria Frattale; Valeria Caponnetto; Alfonsina Casalena; Maurizio Assetta; Maurizio Maddestra; Fabio Marzoli; Giannapia Affaitati; Maria Adele Giamberardino; Stefano Viola; Amleto Gabriele; Francesca Pistoia; Davide Cerone; Carmine Marini; Simona Sacco; Raffaele Ornello
Journal:  J Headache Pain       Date:  2021-01-06       Impact factor: 7.277

6.  Erenumab for headaches in idiopathic intracranial hypertension: A prospective open-label evaluation.

Authors:  Andreas Yiangou; James L Mitchell; Claire Fisher; Julie Edwards; Vivek Vijay; Zerin Alimajstorovic; Olivia Grech; Gareth G Lavery; Susan P Mollan; Alexandra J Sinclair
Journal:  Headache       Date:  2020-12-14       Impact factor: 5.887

7.  MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention.

Authors:  Robert Belvís; Pablo Irimia; Patricia Pozo-Rosich; Carmen González-Oria; Antonio Cano; Javier Viguera; Belén Sánchez; Francisco Molina; Isabel Beltrán; Agustín Oterino; Elisa Cuadrado; Angel Gómez-Camello; Miguel Alberte-Woodward; Carmen Jurado; Teresa Oms; David Ezpeleta; Javier Díaz de Terán; Noemí Morollón; Germán Latorre; Marta Torres-Ferrús; Alicia Alpuente; Raquel Lamas; Carlos Toledano; Rogelio Leira; Sonia Santos; Margarita Sánchez Del Río
Journal:  J Headache Pain       Date:  2021-07-17       Impact factor: 7.277

8.  Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study.

Authors:  Bianca Raffaelli; Rea Kalantzis; Jasper Mecklenburg; Lucas Hendrik Overeem; Lars Neeb; Astrid Gendolla; Uwe Reuter
Journal:  Front Neurol       Date:  2020-05-28       Impact factor: 4.003

9.  Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy.

Authors:  Raffaele Ornello; Alfonsina Casalena; Ilaria Frattale; Amleto Gabriele; Giannapia Affaitati; Maria Adele Giamberardino; Maurizio Assetta; Maurizio Maddestra; Fabio Marzoli; Stefano Viola; Davide Cerone; Carmine Marini; Francesca Pistoia; Simona Sacco
Journal:  J Headache Pain       Date:  2020-04-07       Impact factor: 7.277

10.  Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience.

Authors:  Antonio Russo; Marcello Silvestro; Fabrizio Scotto di Clemente; Francesca Trojsi; Alvino Bisecco; Simona Bonavita; Alessandro Tessitore; Gioacchino Tedeschi
Journal:  J Headache Pain       Date:  2020-06-09       Impact factor: 7.277
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.